SanBio Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SanBio's estimated annual revenue is currently $10.8M per year.(i)
  • SanBio's estimated revenue per employee is $155,000

Employee Data

  • SanBio has 70 Employees.(i)
  • SanBio grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Founded in February 2001 SanBio's scope of business is development, production and sales of regenerative cell medicines. Our mission is to develop regenerative medicines, creating benefits for patients and value for stakeholders. Our vision is to achieve global leadership in the regenerative medicine field using best science and technology, building global revenues and sponsoring successful clinical trials. SanBio focuses on using regenerative cell medicine to treat the disabilies caused by diseases of the central nervous system. Most of these conditions currently have no effective medicinal treatment, and those treatment that do exist generally address disease symptoms and not the underlying cause of the disease. Such conditions afflict a vast number of patients worldwide.As of January, 2016, SanBio had introduced a product for the treatment of chronic motor impairment from ischemic stroke and traumatic brain injury into clinical development in both Japan and the US. In the future, SanBio plans to continue expanding the indications and geographical regions for its products, using both internal development, as well as partnerships and licenses.

keywords:N/A

N/A

Total Funding

70

Number of Employees

$10.8M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SanBio News

2022-04-17 - SanBio (4592 JP): Marketing Approval of First Product ...

SanBio has a pipeline of five other pre-clinical drug candidates, entailing visibility beyond SB623. detail (5-minute read). WHAT'S TRENDING.

2022-04-06 - Argenx, Pharma Two B, SanBio Present at AAN

Argenx, Pharma Two B, SanBio Present at AAN. Published: Apr 05, 2022 By Hannah Chudleigh. Neurology/GettyStock. The American Academy of Neurology's (AAN)...

2022-04-06 - SB623 Demonstrated Sustained Improvement in Motor ...

SanBio is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11M70536%N/A
#2
$13.4M7142%N/A
#3
$22.4M71N/AN/A
#4
$20.9M729%N/A
#5
$9.9M7432%N/A